Not Yet RecruitingPhase 2

Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL

18 participantsStarted 2024-09-01

Plain-language summary

A multicenter, prospective trial to evaluate the efficacy and safety of Selinexor, anti-PD-1 antibody plus Golidocitinib in the treatment of relapsed or refractory Natural Killer / T-cell lymphoma.

Who can participate

Age range14 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Confirmed histological diagnosis of NKTCL nasal type
✓. The subject had received prior adequate anti-lymphoma therapy containing asparaginase
✓. Age 14-75 years old
✓. expected to live longer than 3 months
✓. At least one measurable/evaluable site after diagnostic biopsy before treatment start
✓. ECOG performance status of 0-2
✓. Adequate hematological and organ function; i.e. ANC \>1000 cells /mmc, platelet counts \> 50.000/mmc, Hemoglobin \> 9 g/dl AST, ALT \<3 x ULN; serum bilirubin \< 1.5x ULN (patient with Gilbert disease can be enrolled)Serum creatinine \< 2 x ULN or creatinine clearance \> 50ml/min
✓. Tumor tissue (fresh preferred, archival tissue is also acceptable)

Exclusion criteria

✕. Confirmed histological diagnosis of aggressive NK cell leukemia
✕. Evidence of suspect of CNS disease.
✕. Has an active autoimmune disease that has required systemic treatment in past 2-years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs), including but not limited to myotonia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associate with antiphospholipid syndrome, wegener's granulomatosis, Sjogren syndrome, Guillain-Barre syndrome, multiple sclerosis, vasculitis or glomerulonephritis. The following exception are allowed: patients with autoimmune related hypothyroidism or type I diabetes mellitus who are on stable treatment. Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.
✕. Treatment with systemic immunosuppressive medications, including prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide and anti-tumor necrosis factor (anti-TNF) agents within 2 weeks prior to cycle 1 day 1; inhaled corticosteroids are allowed.
✕. Active infection requiring systemic therapy
✕. History of (non-infectious) pneumonitis that required steroids; evidence of interstitial lung disease or active, non-infectious pneumonitis
✕. Significant cardiovascular disease, myocardial infarction in the previous 3 months, unstable arrhythmias, or unstable angina.
✕. History of other(s) infiltrating cancer(s) in the previous 3 years that were not treated with curative intent or who are still receiving anticancer therapy (including hormone therapy for breast or prostate cancer).

What they're measuring

Best CRR

Timeframe: through study completion, an average of 1 year

Trial details

NCT IDNCT06573138

SponsorRuijin Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-07-01

Contact for this trial

Weili Zhao, Prof.

008602164370045 zwl_trial@163.com

View on ClinicalTrials.gov More Lymphoma, Extranodal NK-T-Cell trials